CD22 Positive

5 registered clinical trials studyying CD22 Positive.

Status	Trial	Sponsor	Phase
Withdrawn	Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ NCT03851081	Roswell Park Cancer Institute	Phase 1 / Phase 2
Withdrawn	Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, NCT04029038	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia NCT03698552	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leuke NCT03094611	M.D. Anderson Cancer Center	Phase 2
Completed	Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and C NCT02311998	M.D. Anderson Cancer Center	Phase 1 / Phase 2